Association of Hormone-Related Characteristics and Breast Cancer Risk by Estrogen Receptor/Progesterone Receptor Status in the Shanghai Breast Cancer Study

被引:74
作者
Bao, Ping-Ping [4 ]
Shu, Xiao Ou [1 ,2 ,3 ]
Gao, Yu-Tang [5 ]
Zheng, Ying [4 ]
Cai, Hui [2 ,3 ]
Deming, Sandra L. [2 ,3 ]
Ruan, Zhi-Xian [5 ]
Su, Yinghao [2 ,3 ]
Gu, Kai [4 ]
Lu, Wei [4 ]
Zheng, Wei [2 ,3 ]
机构
[1] Vanderbilt Univ, Med Ctr, Sch Med, Inst Med & Publ Hlth,Vanderbilt Epidemiol Ctr, Nashville, TN 37203 USA
[2] Vanderbilt Univ, Med Ctr, Sch Med, Div Epidemiol,Dept Med, Nashville, TN 37203 USA
[3] Vanderbilt Univ, Med Ctr, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37203 USA
[4] Shanghai Municipal Ctr Dis Control & Prevent, Shanghai, Peoples R China
[5] Shanghai Canc Inst, Dept Epidemiol, Shanghai, Peoples R China
关键词
breast neoplasms; China; hormones; receptors; estrogen; progesterone; risk factors; women; REPLACEMENT THERAPY; BODY-WEIGHT; PROGESTERONE; WOMEN; MODELS; HEALTH; AGE;
D O I
10.1093/aje/kwr145
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Etiologic differences between subtypes of breast cancer defined by estrogen receptor (ER) and progesterone receptor (PR) status are not well understood. The authors evaluated associations of hormone-related factors with breast cancer subtypes in a population-based case-control study involving 1,409 ER-positive (ER+)/PR-positive (PR+) cases, 712 ER-negative (ER-)/PR-negative (PR-) cases, 301 ER+/PR- cases, 254 ER-/PR+ cases, and 3,474 controls aged 20-70 years in Shanghai, China (phase I, 1996-1998; phase II, 2002-2005). Polytomous logistic regression and Wald tests for heterogeneity across subtypes were conducted. Breast cancer risks associated with age at menarche, age at menopause, breastfeeding, age at first livebirth, waist-to-hip ratio, and oral contraceptive use did not differ by hormone receptor status. Among postmenopausal women, higher parity (>= 2 children vs. 1) was associated with reduced risk (odds ratio (OR) = 0.69, 95% confidence interval (CI): 0.52, 0.91) and higher body mass index (BMI; weight (kg)/height (m)(2)) with increased risk (highest quartile: OR = 2.40, 95% CI: 1.65, 3.47) of the ER+/PR+ subtype but was unrelated to the ER-/PR- subtype (for parity, P-heterogeneity = 0.02; for BMI, P-heterogeneity < 0.01). Hormone replacement therapy (OR = 2.25, 95% CI: 1.40, 3.62) and alcohol consumption (OR = 1.59, 95% CI: 1.01, 2.51) appeared to be preferentially associated with the ER+/PR- subtype. These findings indicate that BMI, parity, hormone replacement therapy, and alcohol consumption may play different roles in subtypes of breast cancer. More research is needed to better understand the etiology of 2 relatively rare subtypes, ER+/PR- tumors and ER-/PR+ tumors.
引用
收藏
页码:661 / 671
页数:11
相关论文
共 41 条
  • [1] Association of physical activity with hormone receptor status: The Shanghai Breast Cancer Study
    Adams, Swann Arp
    Matthews, Charles E.
    Hebert, James R.
    Moore, Charity G.
    Cunningham, Joan E.
    Shu, Xiou-Oi
    Fulton, Jeanette
    Gao, Yutang
    Zheng, Wei
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2006, 15 (06) : 1170 - 1178
  • [2] Althuis MD, 2004, CANCER EPIDEM BIOMAR, V13, P1558
  • [3] Progesterone receptors - animal models and cell signaling in breast cancer - The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis
    Anderson, E
    [J]. BREAST CANCER RESEARCH, 2002, 4 (05): : 197 - 201
  • [4] Estrogen receptor-positive, progesterone receptor-negative breast cancer: Association with growth factor receptor expression and tamoxifen resistance
    Arpino, G
    Weiss, H
    Lee, AV
    Schiff, R
    De Placido, S
    Osborne, CK
    Elledge, RM
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (17): : 1254 - 1261
  • [5] Breast tumours following combined hormone replacement therapy express favourable prognostic factors
    Borgquist, Signe
    Anagnostaki, Lola
    Jirstrom, Karin
    Landberg, Goran
    Manjer, Jonas
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2007, 120 (10) : 2202 - 2207
  • [6] Menopausal Hormone Therapy and Breast Cancer Risk in the NIH-AARP Diet and Health Study Cohort
    Brinton, Louise A.
    Richesson, Douglas
    Leitzmann, Michael F.
    Gierach, Gretchen L.
    Schatzkin, Arthur
    Mouw, Traci
    Hollenbeck, Albert R.
    Lacey, James V., Jr.
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2008, 17 (11) : 3150 - 3160
  • [7] Risk of breast cancer classified by joint estrogen receptor and progesterone receptor status among women 20-44 years of age
    Britton, JA
    Gammon, MD
    Schoenberg, JB
    Stanford, JL
    Coates, RJ
    Swanson, CA
    Potischman, N
    Malone, KE
    Brogan, DJ
    Daling, JR
    Brinton, LA
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 2002, 156 (06) : 507 - 516
  • [8] INSULIN RESISTANCE AND BREAST-CANCER RISK
    BRUNING, PF
    BONFRER, JMG
    VANNOORD, PAH
    HART, AAM
    DEJONGBAKKER, M
    NOOIJEN, WJ
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1992, 52 (04) : 511 - 516
  • [9] Risk factors and hormone-receptor status: epidemiology, risk-prediction models and treatment implications for breast cancer
    Chen, Wendy Y.
    Colditz, Graham A.
    [J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2007, 4 (07): : 415 - 423
  • [10] Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma
    Chen, WY
    Hankinson, SE
    Schnitt, SJ
    Rosner, BA
    Holmes, MD
    Colditz, GA
    [J]. CANCER, 2004, 101 (07) : 1490 - 1500